Daan S. Spoor

Daan S. Spoor

Auto-generated profile, based on publicly available information

Daan S. Spoor

Partner Site Munich, Deutsches Konsortium für Translationale Krebsforschung (dktk), Munich, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in JMIR Research Protocols
Verified
Journal Article
Open access
VWValentin Walker
Valentin Walker
ACAnne Crijns
Anne Crijns
HLHans Langendijk
Hans Langendijk
DSDaan Spoor
Daan Spoor
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
Sophie JacobSophie Jacob
Sophie Jacob
Breast cancer is the most common cancer among women, and radiotherapy plays a major role in its treatment. However, breast cancer radiotherapy can lead to incidental irradiation of the heart, resulting in an increased risk for a variety of heart diseases arising many years after radiotherapy. Therefore, identifying breast cancer patients at the highest risk for radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention, which may contribute to healthy aging. There is still a need for precise knowledge on the relationship between radiation dose to specific cardiac structures and early subclinical cardiac changes and their occurrence over time that could finally lead to cardiac complications. The MEDIRAD EARLY HEART study aims to identify and validate new cardiac imaging and circulating biomarkers of radiation-induced cardiovascular changes arising within first 2 years of breast cancer radiotherapy and to develop risk models integrating these biomarkers combined with precise dose metrics of cardiac structures based on three-dimensional dosimetry. The EARLY HEART study is a multicenter, prospective cohort study in which 250 women treated for breast cancer and followed for 2 years after radiotherapy will be included. Women treated with radiotherapy without chemotherapy for a unilateral breast cancer and aged 40-75 years meet the inclusion criteria. Baseline and follow-up data include cardiac measurements based on two-dimensional speckle-tracking echocardiography, computed tomography coronary angiography, cardiac magnetic resonance imaging, and a wide panel of circulating biomarkers of cardiac injury. The absorbed dose will be evaluated globally for the heart and different substructures. Furthermore, the dose-response relationship will allow modeling the radiation-induced occurrence and evolution of subclinical cardiac lesions and biomarkers to develop prediction models. This study details the protocol of the MEDIRAD EARLY HEART study and presents the main limits and advantages of this international project. The inclusion of patients began in 2017. Preliminary results are expected to be published in 2019, and complete analysis should be published in 2021. The MEDIRAD EARLY HEART study will allow identifying the main cardiac imaging and blood-based determinants of radiation-induced cardiac injuries to better propose primary and secondary preventive measures in order to contribute to enhanced patient care and quality of life. ClinicalTrials.gov NCT03297346; https://clinicaltrials.gov/ct2/show/NCT03297346 (Archived by WebCite at http://www.webcitation.org/72KS7MIUU). RR1-10.2196/9906.

1 April 2025 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
JLJérôme Lamy
Jérôme Lamy
DSDaan S. Spoor
Daan S. Spoor
JLJohannes A. Langendijk
Johannes A. Langendijk
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
AEArantxa Eraso
Arantxa Eraso
KBKai Borm
Kai Borm
Higher cardiac radiation doses in participants with breast cancer treated with radiation therapy after lumpectomy were associated with increased risk of reduced left ventricular global longitudinal strain at 2-year follow-up cardiac MRI.

8 June 2023 in The Breast
Verified
Journal Article
Open access
DSD.S. Spoor
D.S. Spoor
VBV.A.B. van Den Bogaard
V.A.B. van Den Bogaard
NSN.M. Sijtsema
N.M. Sijtsema
PMP. Van der Meer
P. Van der Meer
GBG.H. de Bock
G.H. de Bock
ACA.P.G. Crijns
A.P.G. Crijns
To provide more insight into late treatment-related toxicities among breast cancer (BC) survivors by comparing morbidities and risk factors between BC survivors and age-matched controls. All female participants diagnosed with BC before inclusion in Lifelines, a population-based cohort in the Netherlands, were selected and matched 1:4 to female controls without any oncological history on birth year. Baseline was defined as the age at BC diagnosis. Outcomes were obtained from questionnaires and functional analyses performed at entry to Lifelines (follow-up 1; FU1) and several years later (FU2). Cardiovascular and pulmonary events were defined as morbidities that were absent at baseline but present at FU1 or FU2. The study consisted of 1,325 BC survivors and 5,300 controls. The median period from baseline (i.e., BC treatment) to FU1 and FU2 was 7 and 10 years, respectively. Among BC survivors more events of heart failure (OR: 1.72 [1.10-2.68]) and less events of hypertension (OR: 0.79 [0.66-0.94]) were observed. At FU2, more electrocardiographic abnormalities were found among BC survivors compared to controls (4.1% vs. 2.7%, respectively; p = 0.027) and Framingham scores for the 10-year risk of coronary heart disease were lower (difference: 0.37%; 95% CI [-0.70 to -0.03%]). At FU2, BC survivors had more frequently a forced vital capacity below the lower limit of normal than controls (5.4% vs. 2.9%, respectively; p = 0.040). BC survivors are at risk of late treatment-related toxicities despite a more favourable cardiovascular risk profile compared to age-matched female controls.

1 June 2026 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
EMElie Mousseaux
Elie Mousseaux
DCDamian Craiem
Damian Craiem
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
Sophie JacobSophie Jacob
Sophie Jacob
AEArantxa Eraso
Arantxa Eraso
SCSusana Constantino
Susana Constantino
Two years after breast cancer radiotherapy, cardiac CT demonstrated dose-associated progression of coronary artery calcification, particularly in the presence of preexisting calcification, while coronary stenosis progression was unrelated to radiation dose.

22 January 2018 in JMIR Preprints
Verified
Preprint
Open access
VWValentin Walker
Valentin Walker
ACAnne Crijns
Anne Crijns
HLHans Langendijk
Hans Langendijk
DSDaan Spoor
Daan Spoor
RVRozemarijn Vliegenthart
Rozemarijn Vliegenthart
Sophie JacobSophie Jacob
Sophie Jacob
BACKGROUND Breast cancer (BC) is the most common cancer among women and radiotherapy (RT) plays a major role in its treatment. However, BC RT can lead to incidental irradiation of the heart, resulting in an increased risk of a variety of heart diseases arising many years after radiotherapy. Therefore, identifying BC patients with the highest-risk of radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention, which may contribute to healthy ageing. There is still a need of precise knowledge on the relationship between radiation dose to specific cardiac structures and early subclinical cardiac changes and their occurrence in time that could finally lead to cardiac complications. OBJECTIVE The MEDIRAD EARLY HEART study aims to identify and validate new cardiac imaging and circulating biomarkers of radiation-induced cardiovascular changes arising in the first 2 years after BC RT and to develop risk models integrating these biomarkers combined with precise dose metrics of cardiac structures based on 3D-dosimetry. METHODS EARLY HEART study is a multicenter prospective cohort study that will include 250 women treated for breast cancer and followed for 2 years after RT. Women treated with RT without chemotherapy, for a unilateral breast cancer and aged 40 to 75 years meet the inclusion criteria. Baseline and follow-up data include cardiac measurements based on 2D-speckle-tracking-echocardiography, on coronary computed tomography angiography, on cardiac magnetic resonance imaging and a wide panel of circulating biomarkers of cardiac injury. The absorbed dose is evaluated globally for the heart and different substructures. Dose-response relationship will allow modeling radiation-induced occurrence and evolution of subclinical cardiac lesions and biomarkers in order to develop prediction models. RESULTS The article details the protocol of the MEDIRAD EARLY HEART study, and presents main limits and advantages of this international project. Inclusion of patients began in 2017. Preliminary results are expected to be published in 2019, and complete analysis should be published in 2021. CONCLUSIONS The MEDIRAD EARLY HEART study will allow identifying the main cardiac imaging and blood-based determinants of radiation-induced cardiac injuries to better propose primary and secondary preventive measures in order to contribute to enhanced patients’ care and quality of life. CLINICALTRIAL Clinicaltrials.gov NCT03297346 - https://clinicaltrials.gov/ct2/show/NCT03297346